Summary: Administration of L-caniitine or betamethasone to pregnant rats failed to increase either the total phospholipid or dipalmitoylphosphatidylcholine (DPPC) contents in foetal rat lungs on the 20th day of j gestation, eompared to cpntrols. The combined administration of betamethasone (0.3 mg/kg) and L-carnitine ; (80 mg/kg) resulted in a pronounced increase of dipalmitoylphosphatidylcholine (7.8 ±2.5 mg/g dry weight) j coinpared with the control group (5.4 ± 1.8 mg/g dry weight), and compared with the groups receiving betamethasone (5.9 ±1.9 mg/g dry weight) or L-carnitine (5.6 + 1.5 mg/g dry weight) alone. The proportion of dipalmitoylphosphatidylcholine in the phosphatidylcholine species increased from 20.9 ±2.1% in the foetal lungs of the control group to 22.6 ± 5.0% in the L-carnitine group, to 24.3 + 3.3% (p < 0.01) in the betämethasone-i-carnitine (20 mg/kg) group, to 25.2 ± 3.5% (p < 0.01) in the betamethasone group, to 27.1 + 2.6% (p < 0.01) in the betamethasone-L-carnitine (40 mg/kg) group, and to 28.4 ± 3.7% (p < 0.01) in the betamethasone-L^carnitine (80 mg/kg) group, while the palmitic acid portion in the phosphatidylcholine fatty acids was nearly unchanged. A pronounced increase of palmitoyl-myristoyl phosphatidylcholine (PC-30), the second disaturated phosphatidylcholine species present in lungs in significant amounts beside dipalmitoylphosphatidylcholine, was noted only in betamethasone treated animals. Furthermore, after betamethasone and betamethasone^carnitine treatment, a significant diminution (p < 0.01) of the proportion of palmitoyl-palmitoleyl phosphatidylcholine (16 : 0/16 : l-PC) in the phosphatidylcholine species was demonstrated. After L-carnitine and betamethasone-L-carnitine treatment a significant increase (p < 0.01) of the Proportion of palmitoleyl-palmitoyl phosphatidylcholine (16 :1/16 : 0-PC) in the phosphatidylcholine species was found. Administration of L-carnitine to pregnant rats (either alone or in combination with betamethasone) resulted in a significant elevation (p < 0.01) of the carnitine levels in the foetal lungs to approximately twice those of the controls. The results suggest that a betamethasone-L-carnitine combination has both additive effects and effects specific for the combination, neither of which are found when carnitine or betamethasone is administered alone.
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Materials and Methods
Seventy-five female Wistar rats of stock Ch bb-Thom with an average weight of 300 g and an expected gestation period of 23 days were randomized and divided into six groups. The gestational age was known within 24 hours. The rats were treated intraperitoneally from the 16th to the 19th day of gestation by the following schedule: l ml/day physiological saline l ml/day distilled water l ml/day distilled water l ml/day distilled water l ml/day distilled water l ml/day distilled water
Higher carnitine doses (60, 80,100 nag/kg) showed effects which were not significantly different from those with 20 mg/kg body weight.
Preparation of lung tissue
Immediately after delivery the foetal trachea was clamped before spontaneous Inspiration could occur. The foetuses were thoracotomized by means of parasternal incision. The foetal lungs were then grouped according to litter in order to preclude station-related differences. The foetal lungs were homogenized, extracted, and washed using the method of Folch et al. (5) .
Phospholipid analysis
Total phospholipids were assayed by a mpdified version of Bartletfs method (6) . The main phpspholipid classes were separated äs bands by tidiiflayer chromatography using the solvent System chloroform/methanol/lO g/l potassium Chloride solution (volümes, 43 +47+4) (4). 1,2 Dipalmitoyl-sn-glycero-3-phosphpchpline (PPPC) and the glycero-3-phosphocholine species composition were assayed äs the corresponding diacylglycerpl trimethylsiiylether derivatives by gas-liquid chromatography with glass capillary columns (7, 8) . Phosphatidylcholine fatty acids were determined äs methyl ester derivatives by gasliquid chromatography with glass capillary columns.
Carnitine assay
The tissue was flash-frozen immediately after removal. The perchloric acid extracts were üsed for assaying free and shortchain acylcarnitine. The carnitine esters were saponified and assayed äs free carnitine by radioenzymatic means (9), with two modiflcations: HEPES instead of TRIS buffer (10) , and N-ethylmaleimide instead of tetrathionate (11).
Chemicals "L-Carnitin-Leopold" was obtained from Leopold Ltd. (Graz, Austria). Chloroform, methanol, pyridine, hexamethyldisilazane, thin-layer chromatography plates (silica gel 60), and HE-PES were obtained from E. Merck (Darmstadt, F. R. G.). Bacillus ce/ms-derived phospholipase C and carnitine acetyltransferase were obtained from Boehringer-Mannheim (R R. G.). Labeled acetylcoenzyme A was obtained from New England Nuclear (Boston, Mass.). N-ethylmaleimide and dimyristoyl-sn-glycero-3-phosphocholine were supplied by Sigma Chemical Company (St. Louis, MO.).
Statistical analysis
Statistical cornparisons between the control group and the treated groups were made using analysis of variance followed by Dünnet*s t-test for multiple comparison.
Results

Total phospholipid content
Only small differences in the total phospholipid content in foetal rat* lungs were found in the different treatment groups (data not shown).
Dipalmitoylphosphatidylcholine
Both betamethaspne and L-carnitine treatments induced only a moderate increase in the dipalmitoylphosphatidylcholine content compared with the control group. However, the combined administration of betamethasone and Z/-carnitine resulted in a marked increase in the dipalmitöylphosphatidylcholine content (tab. 1). The proportion of dipalmitöylphospha-tidylcholine in the phosphatidylcholine species exhibited a significant rise (p < 0.01) in the betamethasone group, and the betamethasone-L-carnitine combination groups. Only a moderate response to Lcarnitine administration was noted (tab. 1). methasone-L-carnitine groups (20 mg/kg and 40 mg/ kg) there is a further decrease, whereas after administration of the betamethasone-L-carnitine (80 mg/kg) combination, the same level äs in the betamethasone group was found.
No increase was found in the proportion of 16: l/ 16:0-PC following betamethasone treatment, äs compared with the control group, whereas a marked increase was found after L-carnitine administration. The betamethasone-L-carnitine combination groups showed significantly (p < 0.01) enhanced levels.
In quantitative terms (mg/g dry weight), the same effects described above were found for both 16: O/ 16 :1-PC and 16 :1/16 : 0-PC (data not shown).
phosphatidylcholiiie, which consists of dipalmitoylphosphatidylcholine and PC-30. It was therefore of interest to examine whether the different treatments would affect dipalmitoylphosphatidylchöline exclüsi-vely, or both disaturated species. As shown in table 2, betamethasone treatment resulted in an increase of the PC-30 portion in the phosphatidylcholine species compared with the controls, whereas no response to L-carnitine was noted. It is of interest that the betamethasone-L-carnitine (40 mg/kg) combination resulted in a moderate enhancement, whereas in the betamethasone-L-carnitine (20 mg/kg and 80 mg/kg) combination groups no response was noted.
Composition of the phosphatidylcholine species (tab. 2)
Palmitoyl-myristoyl phosphatidylcholine (PC-30): most commonly used methods for surfactant determination are based on the determination of disaturated Composition fatty acids of the phosphatidylcholine Table 3 shows the relative composition of the esterified fatty acids in foetal hing phosphatidylcholine. We have previously shown that each fatty acid is present in more than one phosphatidylcholine species Tab. 2. Relative phosphatidylcholine species composition in foetal rat lungs*). Thus, it is not surprising that the alterations in the phosphatidylcholine fatty acid pattern are less pronounced compared with the marked changes of the phosphatidylcholine species composition (tab. 2). In spite of the fact that many studies on the Stimulation of surfactant synthesis are based on the portion of palmitic acid in total fatty acids of hing phosphatidylcholine, it is of interest to note that in the present study, no accordance between the proportion of palmitic acid and the dipalmitoylphosphatidylcholine Content was found (tab. l, 3). Carnitine Table 4 shows the content of total carnitine in the foetal lungs. Betamethasone failed to ißfluence the carnitine content. Materaal L-carnitine administration (20 mg/kg) resulted in a significant increase (p < 0.01). The same carnitine level was attained following treatment with 20 mg/kg or with 40 mg/kg betamethasone-L-carnitine. Administration of a betamethasone-jL-carnitine (80 mg/kg) combination resulted in a further, but not dose-related increase. The Proportion of short-chain acyl-carnitine in the total carnitine was relatively constant in all groups (data not shown). Foetal weight and foetal lung weight (tab. 5)
As shown in numerous animal experiments maternal treatment with corticosteroids resulted in a decrease of foetal weight and in a marked reduction of the foetal lung weight (13 -16) . Also, in the present study the lowest foetal body weights and foetal lung weights were found in the betamethasone-treated group (tab. 5). Administration of L-carnitine resulted in an enhancement of both foetal weight and foetal lung weight (p < 0.01) compared with the control group and the other treatment groups. Interestingly, treatment with the betamethasone-L-carnitine (80 mg/kg) combination resulted in a reduction of the foetal lung weight comparable to that of the betamethasone group.
Tab. 5. Body weight and lung weight of the foetal rats*). 
Discussion
Weinhold et al. (17) have shown that 50 to 60% of foetal rats delivered two days prematurely survive when placedan an incubator, while foetuses delivered three days before term did not survive. In the present study the foetal rats were delivered three days before term, in contrast to previous studies in which delivery was performed two days prematurely (4).
Betamethasone
It has been reported that relatively low doses of betamethasone (0.25 mg/kg) given to the pregnant rabbit increase the rate of choline incorporation into phosphatidylcholine by foetal lung. However, larger doses maternally administered cause foetal death, apparently due to premature aging of the placenta (18) . In the present study no increase in total phospholipid-and dipalmitoylphosphatidylcholine-contents with respect to dry weight were found after administration of 0.3 mg/kg betamethasone to the mother animals. This is in accordance with studies on rhesus monkeys (19, 20) . Funkhäuser et al. (21) showed that dexamethasone exposure does not increase the total amount of surfactant per lung.
It is of interest to note that betamethasone treatment also influences palmitoyl-myristoyl phosphatidylcholine (PC-30) both in quantitative and relative terms (tab. 2). The role of PC-30 is unclear. Goerke et al. (22) reported that PC-30 did not meet with all of the criteria of surfactant material.
As reported previously (4) the two monoenic PC-32 species (16:0/16: l-PC and 16 :1/16 : 0-PC) are of special interest, because the types of phosphatidylcholine that they contain are different in foetal lungs and the lungs of adult animals (tab. 1).
These results were substantiated by the study of Longmuir et al. (23) . An unusually high portion of palmitoleic acid (16:1), which was more than oüe-fourth of the total fatty acids of the lamellar body phosphatidylcholine frpm foetal rabbit lungs, was found.
Carnitine
In contrast to glucocorticoids, no toxic side effects are produced by L-carnitine (L-3-hydroxy-4-N-trimethylaminobutyrate) (24, 25) . In addition to the well established role of carnitine in the oxidation of fatty acids in mitochondria, several additional fuiictions of carnitine in cell metaßollsm have been reported (summarized recently, (4)).
In the rat foetus plasma (26) and tissue (27, 28) levels of both free and short-chain acyl-carnitine are low and increa.se up to parturition. As in the foetal rat, the rate of carnitine synthesis is low in the human foetus (29). Furthermore, maternal plasma carnitine concentrations are strongly reduced during pregnancy (29-31).
The rate of fatty acid oxidation is low during the intrauterine phase (32) . Shortly after parturition there is a striking increase in energy production by fatty acid oxidation due to the interrupted maternal glucose supply. At this time tissue carnitine levels must be sufficiently high for free fatty acid mobilization from endogenous Stores (33, 34) äs well äs for fatty acid oxidation in various tissues, accompanied in the liver by ketone body production (35) . It is of interest to note that the rate of fatty acid synthesis from acetoacetate is two or three times greater than from glucose in developing rat lung . (36) . Thereföre, immediately after parturition, a^sufficient anioünt of ketone bodies is necessary for the synthesis of surfactant precursors to meet the need for surfactant postnatally. Administration of L-carnitine to pregnant rats elevated the carnitine in foetal lungs to a level approximately twice that of the controls (tab. 4) and roughly equivalent to that of untreated animals at term.
Carnitine-betamethasone combination
The combined administration of betamethasone and L-carnitine resulted in two different effects: additive or subtractive effects, and effects apparently specific for the combination.
Using a Standard betamethasone dose of 0.3 mg/kg the best results were obtained in combination with 80 mg/kg L-carnitine. The enhancement of the dipalmitoylphosphatidylcholine content of foetal lungs is obviously specific for the combination, since this effect was not found after betamethasone or L-carnitine treatment alone (tab. 1). However, there was rather an additive effect of the betamethasone-Lcarnitine combination on PC-30 and 16:1/16: 0-PC.
Little is known about interactions of carnitine and glucocorticoids. In studies on carnitine transport across the plasma membrane an increased uptake in the presence of prednisolone was noted (37, 38). In human systemic carnitine deficiency, corticosteroid treatment is known to be beneficial (39) . It is also possible that the effect of the betamethasone-L-carnitine combination is mediated by other mechanisms. Chaudhary et al. (40) found an increased cyclic AMP (cAMP) level in foetal rat lungs after dexamethasone treatment. An important role of cAMP in the regulation of surfactant production by foetal lungs has been postulated (41) . Glucocorticoids promote the conversion of foetal thyroxine (T 4 ) to triiodothyronine (T 3 ) rather than reverse T 3 , and this could account for the increase in T 3 levels (42) . Accelerated lung maturation after treatment either with T 4 or T 3 has been reported. Since T 4 enhances the activity of enzymes involved in carnitine metabolism it was also of interest to investigate the effect of an L-carnitinethyroxine combination. The results of these experiments will be published elsewhere.
